The U.S. Supreme Court turned away a novel case by Arizona seeking to recover billions of dollars that the state has said that members of the Sackler family – owners of Purdue Pharma LP – funneled out of the OxyContin maker before the company filed for bankruptcy in September 2019.
Merck & Co. Inc. is buying ArQule Inc. for $2.7 billion, seeking to tap into the drug developer’s experimental blood cancer therapy that targets genetic mutations.
HIV-prevention advocacy group PrEP4All Collaboration filed a petition with the U.S. Patent and Trademark Office alleging that Gilead Sciences intentionally delayed the development of a safer drug for human immunodeficiency virus.
U.S. Food and Drug Administration staffers reviewing Correvio Pharma Corp.’s Brinavess said they did not believe the benefits of the heart drug outweighed the therapy’s risks, sending the company’s shares down nearly 38 percent.
Hospital groups challenged the Trump administration’s rule that requires hospitals to be more transparent about prices they charge patients for healthcare services, according to a filed lawsuit.
Johnson & Johnson said recent tests showed that Johnson’s Baby Powder was free of asbestos, after FDA investigations reported trace amounts of the material in the product earlier in 2019.
Johnson & Johnson said recent tests showed that Johnson’s Baby Powder was free of asbestos, after FDA investigations reported trace amounts of the material in the product earlier in 2019.
Tokyo-based Astellas Pharma announced plans to acquire San Francisco-based Audentes Therapeutics for $60 per share in cash, representing a total equity value of about $3 billion.
Seattle Genetics is looking for a quicker path to resolution with Daiichi Sankyo over antibody drug conjugate technology that both companies claim ownership of.
Powder Keg: FDA bowed to industry for decades as alarms were sounded over talc
Asbestos, Business, Cancer Prevention Coalition, Consumers, Cosmetics, Department Of Justice, FDA, FDA/Regulatory, Food Safety and Applied Nutrition (JIFSAN), Health Concerns, Lawsuits, Minerals, Talc, Talc-Based Products, U.S. Securities and Exchange Commission (SEC), World Health OrganizationOver the past 50 years, the FDA has relied upon – and often deferred to – industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found.
